NASDAQ:PMCB Nuvilex (PMCB) Stock Price, News & Analysis $0.55 0.00 (0.00%) Closing price 08/14/2026 03:59 PM EasternExtended Trading$0.55 0.00 (0.00%) As of 08/14/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock About Nuvilex Stock (NASDAQ:PMCB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nuvilex alerts:Sign Up Key Stats Today's Range$0.54▼$0.5750-Day Range$0.55▼$0.8352-Week Range$0.53▼$1.51Volume131,483 shsAverage Volume132,572 shsMarket Capitalization$5.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada. Read More Nuvilex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScorePMCB MarketRank™: Nuvilex scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingNuvilex has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageNuvilex has only been the subject of 1 research reports in the past 90 days.Read more about Nuvilex's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvilex is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvilex is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvilex has a P/B Ratio of 0.18. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nuvilex's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.05% of the float of Nuvilex has been sold short.Short Interest Ratio / Days to CoverNuvilex has a short interest ratio ("days to cover") of 1.91, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nuvilex has recently decreased by 9.44%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvilex does not currently pay a dividend.Dividend GrowthNuvilex does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentNuvilex has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nuvilex this week, compared to 0 articles on an average week.Search Interest1 people have searched for PMCB on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nuvilex insiders have not sold or bought any company stock.Percentage Held by Insiders10.98% of the stock of Nuvilex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions34.24% of the stock of Nuvilex is held by institutions.Read more about Nuvilex's insider trading history. Receive PMCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvilex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PMCB Stock News HeadlinesPharmaCyte Biotech, Inc. Increases Stake in TNF Pharmaceuticals Around Recent License for Breakthrough Light Speed Computing Platform for Use in Cryptocurrency ApplicationsSeptember 2, 2025 | businesswire.comPharmaCyte Biotech, Inc. Announces Closing of $7 Million FinancingAugust 20, 2025 | businesswire.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.August 17 at 1:00 AM | Base Camp Trading (Ad)PharmaCyte Biotech, Inc. Announces $7 Million Capital Raise Led by Existing InvestorsAugust 18, 2025 | businesswire.comMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comPMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comSee More Headlines PMCB Stock Analysis - Frequently Asked Questions How have PMCB shares performed this year? Nuvilex's stock was trading at $0.7240 at the beginning of 2026. Since then, PMCB shares have decreased by 23.9% and is now trading at $0.5510. How were Nuvilex's earnings last quarter? Nuvilex Inc. (NASDAQ:PMCB) released its quarterly earnings results on Thursday, December, 18th. The company reported ($0.32) EPS for the quarter. How do I buy shares of Nuvilex? Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvilex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvilex investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), ASML (ASML), GE Aerospace (GE), Oracle (ORCL) and Nokia (NOK). Company Calendar Last Earnings12/18/2025Today8/17/2026Next Earnings (Estimated)8/24/2026Fiscal Year End4/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (7m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 PMCB's financial health is in the Red zone, according to TradeSmith. PMCB has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PMCB CIK1157075 Webpharmacyte.com Phone917-595-2850Fax917-595-2851Employees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.42 million Net MarginsN/A Pretax MarginN/A Return on Equity0.25% Return on Assets0.18% Debt Debt-to-Equity RatioN/A Current Ratio45.30 Quick Ratio45.30 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book0.18Miscellaneous Outstanding Shares10,740,000Free Float9,557,000Market Cap$5.92 million OptionableOptionable Beta0.57 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:PMCB) was last updated on 8/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvilex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvilex With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
